REGN
Regeneron Pharmaceuticals insider trading
Health Care · Heavy selling
Close · Oct 5, 2026
$726.47
+24.7% over 12 months
Share price and insider trades
REGN closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$12.9M
Insiders buying0
Insiders selling7
Valuation, profit and volume
P/E (trailing)n/aSector median 24.5
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Regeneron Pharmaceuticals insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $12.9M. 77 of 84 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales. 54 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 3SEC | Marion MccourtEvp Commercial | Sell Plan | 1,215 | $850.00 | $1.0M | -14.5% | — |
| Sep 3SEC | Marion MccourtEvp Commercial | Sell Plan | 1,131 | $857.39 | $970K | -15.3% | — |
| Sep 3SEC | Kathryn GuariniDirector | Sell Plan | 400 | $850.00 | $340K | -14.5% | — |
| Aug 12SEC | Huda Y ZoghbiDirector | Sell Plan | 800 | $800.00 | $640K | -9.2% | — |
| Aug 12SEC | Kathryn GuariniDirector | Sell Plan | 400 | $800.00 | $320K | -9.2% | — |
| Jul 7SEC | Arthur F RyanDirector | Sell Plan | 200 | $650.15 | $130K | +11.7% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 24 | $703.46 | $17K | +3.3% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 15 | $704.28 | $11K | +3.2% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 15 | $702.46 | $11K | +3.4% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 14 | $705.56 | $10K | +3.0% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 7 | $706.74 | $5K | +2.8% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 6 | $709.45 | $4K | +2.4% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 5 | $711.49 | $4K | +2.1% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 5 | $701.76 | $4K | +3.5% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 4 | $707.40 | $3K | +2.7% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 2 | $714.13 | $1K | +1.7% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 2 | $710.87 | $1K | +2.2% | — |
| May 4SEC | Arthur F RyanDirector | Sell Plan | 1 | $712.09 | $712 | +2.0% | — |
| Apr 3SEC | Arthur F RyanDirector | Sell Plan | 40 | $779.71 | $31K | -6.8% | — |
| Apr 3SEC | Arthur F RyanDirector | Sell Plan | 14 | $775.58 | $11K | -6.3% | — |
| Apr 3SEC | Arthur F RyanDirector | Sell Plan | 13 | $776.62 | $10K | -6.5% | — |
| Apr 3SEC | Arthur F RyanDirector | Sell Plan | 9 | $777.42 | $7K | -6.6% | — |
| Apr 3SEC | Arthur F RyanDirector | Sell Plan | 8 | $774.58 | $6K | -6.2% | — |
| Apr 3SEC | Arthur F RyanDirector | Sell Plan | 8 | $773.59 | $6K | -6.1% | — |
| Apr 3SEC | Arthur F RyanDirector | Sell Plan | 4 | $778.24 | $3K | -6.7% | — |
| Apr 3SEC | Arthur F RyanDirector | Sell Plan | 3 | $772.76 | $2K | -6.0% | — |
| Apr 3SEC | Arthur F RyanDirector | Sell Plan | 1 | $771.32 | $771 | -5.8% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 20 | $789.28 | $16K | -8.0% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 20 | $788.96 | $16K | -7.9% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 11 | $785.48 | $9K | -7.5% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 10 | $783.62 | $8K | -7.3% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 9 | $784.48 | $7K | -7.4% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 7 | $786.61 | $6K | -7.6% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 7 | $777.46 | $5K | -6.6% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 5 | $779.69 | $4K | -6.8% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 3 | $780.69 | $2K | -6.9% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 2 | $787.34 | $2K | -7.7% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 2 | $782.62 | $2K | -7.2% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 2 | $781.21 | $2K | -7.0% | — |
| Mar 3SEC | Arthur F RyanDirector | Sell Plan | 2 | $778.30 | $2K | -6.7% | — |
| Feb 23SEC | Huda Y ZoghbiDirector | Sell Plan | 331 | $780.45 | $258K | -6.9% | — |
| Feb 23SEC | Huda Y ZoghbiDirector | Sell Plan | 298 | $782.10 | $233K | -7.1% | — |
| Feb 23SEC | Huda Y ZoghbiDirector | Sell Plan | 220 | $783.29 | $172K | -7.3% | — |
| Feb 23SEC | Huda Y ZoghbiDirector | Sell Plan | 209 | $781.28 | $163K | -7.0% | — |
| Feb 23SEC | Huda Y ZoghbiDirector | Sell Plan | 208 | $779.55 | $162K | -6.8% | — |
| Feb 23SEC | Huda Y ZoghbiDirector | Sell Plan | 160 | $784.45 | $126K | -7.4% | — |
| Feb 23SEC | Huda Y ZoghbiDirector | Sell Plan | 56 | $785.61 | $44K | -7.5% | — |
| Feb 23SEC | Huda Y ZoghbiDirector | Sell Plan | 53 | $778.47 | $41K | -6.7% | — |
| Feb 23SEC | Huda Y ZoghbiDirector | Sell Plan | 50 | $775.50 | $39K | -6.3% | — |
| Feb 23SEC | Huda Y ZoghbiDirector | Sell Plan | 49 | $774.68 | $38K | -6.2% | — |
| Feb 23SEC | Huda Y ZoghbiDirector | Sell Plan | 4 | $790.00 | $3K | -8.0% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 563 | $778.35 | $438K | -6.7% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 521 | $776.43 | $405K | -6.4% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 391 | $777.51 | $304K | -6.6% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 205 | $779.56 | $160K | -6.8% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 144 | $783.23 | $113K | -7.2% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 75 | $780.06 | $59K | -6.9% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 57 | $777.56 | $44K | -6.6% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 53 | $785.72 | $42K | -7.5% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 37 | $782.67 | $29K | -7.2% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 26 | $781.37 | $20K | -7.0% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 20 | $775.95 | $16K | -6.4% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 12 | $778.53 | $9K | -6.7% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 10 | $776.59 | $8K | -6.5% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 5 | $781.48 | $4K | -7.0% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 5 | $779.41 | $4K | -6.8% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 3 | $783.34 | $2K | -7.3% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 2 | $786.29 | $2K | -7.6% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 1 | $787.82 | $788 | -7.8% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 1 | $785.71 | $786 | -7.5% | — |
| Feb 11SEC | Jason PitofskySvp Controller | Sell Plan | 1 | $784.66 | $785 | -7.4% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 1 | $784.59 | $785 | -7.4% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 1 | $782.53 | $783 | -7.2% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 1 | $780.09 | $780 | -6.9% | — |
| Feb 11SEC | Arthur F RyanDirector | Sell Plan | 1 | $775.63 | $776 | -6.3% | — |
| Jan 8SEC | Bonnie L BasslerDirector | Sell Plan | 1,500 | $800.00 | $1.2M | -9.2% | — |
| Nov 24SEC | Bonnie L BasslerDirector | Sell Plan | 760 | $750.00 | $570K | -3.1% | — |
| Nov 10SEC | Jason PitofskyVp Controller | Sell | 431 | $651.43 | $281K | +11.5% | — |
| Oct 31SEC | Christine A PoonDirector | Sell | 2,735 | $653.50 | $1.8M | +11.2% | — |
| Oct 31SEC | Christine A PoonDirector | Sell | 1,915 | $654.42 | $1.3M | +11.0% | — |
| Oct 31SEC | Christine A PoonDirector | Sell | 712 | $656.50 | $467K | +10.7% | — |
| Oct 31SEC | Christine A PoonDirector | Sell | 650 | $652.68 | $424K | +11.3% | — |
| Oct 31SEC | Christine A PoonDirector | Sell | 388 | $657.29 | $255K | +10.5% | — |
| Oct 31SEC | Christine A PoonDirector | Sell | 100 | $655.10 | $66K | +10.9% | — |
Insiders at Regeneron Pharmaceuticals
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Christine A PoonDirector | — | $4.3M | Jan 6, 2026 | — |
| Marion MccourtEvp Commercial | — | $2.0M | Sep 3, 2026 | — |
| Huda Y ZoghbiDirector | — | $1.9M | Aug 12, 2026 | — |
| Jason PitofskySvp Controller | — | $1.9M | Feb 11, 2026 | — |
| Bonnie L BasslerDirector | — | $1.8M | Jan 8, 2026 | — |
| Kathryn GuariniDirector | — | $660K | Sep 3, 2026 | — |
| Arthur F RyanDirector | — | $435K | Jul 7, 2026 | — |
| Joseph J LarosaGeneral Counsel | — | — | Aug 21, 2026 | — |
| Christopher R. FenimoreCFO | — | — | Aug 20, 2026 | — |
| Michael S BrownDirector | — | — | Jan 6, 2026 | — |
| N Anthony ColesDirector | — | — | Jan 6, 2026 | — |
| George L SingDirector | — | — | Jan 6, 2026 | — |
| Joseph L GoldsteinDirector | — | — | Jan 6, 2026 | — |
| Craig B. ThompsonDirector | — | — | Jan 6, 2026 | — |
| David P SchenkeinDirector | — | — | Jan 6, 2026 | — |
| Leonard S SchleiferCEO, President | — | — | Jan 5, 2026 | — |
| George YancopoulosPresident, Chair | — | — | Jan 5, 2026 | — |
| Andrew J MurphyEvp Research | — | — | Dec 11, 2025 | — |
| Plew Daniel P VanEvp & General Mgr, Industrial | — | — | Dec 11, 2025 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
Common questions about REGN insiders
Are Regeneron Pharmaceuticals insiders buying REGN stock?
In the past 12 months, 0 insiders reported open-market purchases of REGN worth $0.
Are Regeneron Pharmaceuticals insiders selling REGN stock?
7 insiders reported sales worth $12.9M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.